A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).

Ferdinandos Skoulidis,Joel W. Neal,Wallace Akerley,Paul K. Paik,Thales Papagiannakopoulos,Karen L. Reckamp,Jonathan W. Riess,Yonchu Jenkins,Sacha Holland,Francesco Parlati,Yijing Shen,Samuel H. Whiting,Naiyer A. Rizvi

A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).

2020

Ferdinandos Skoulidis
Joel W. Neal
Wallace Akerley
Paul K. Paik
Thales Papagiannakopoulos
Karen L. Reckamp
Jonathan W. Riess
Yonchu Jenkins
Sacha Holland
Francesco Parlati
Yijing Shen
Samuel H. Whiting
Naiyer A. Rizvi

TPS9627Background: Mutational activation of the KEAP1/NRF2 pathway occurs in >20% of NSCLC patients (pts). KEAP1/NRF2 activation protects tumor cells from diverse forms of oxidative stress and prom...

Keywords:

Lung cancer
Oncology
non squamous
Glutaminase
Chemotherapy
Internal medicine
Pembrolizumab
first line treatment
Pathology
Randomized controlled trial
Medicine
Placebo
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations